Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-03-15
2000-08-22
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514264, A61K 3152, A01N 4390
Patent
active
061073032
ABSTRACT:
A method of treating Epstein Barr virus infection in humans by administering a pharmaceutically effective amount of an antiviral agent selected from a group consisting of acyclovir, famciclovir, valacyclovir and a pharmaceutically acceptable salt thereof is provided.
REFERENCES:
patent: 4199574 (1980-04-01), Schaeffer
patent: 4435449 (1984-03-01), Sterm
patent: 4609662 (1986-09-01), Krenitsky
patent: 4942166 (1990-07-01), Harnden et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5061708 (1991-10-01), Krenitsky
patent: 5079252 (1992-01-01), Beauchamp
patent: 5164395 (1992-11-01), Blumenkopf
patent: 5284837 (1994-02-01), Lindborg et al.
patent: 5318974 (1994-06-01), Beauchamp
patent: 5405850 (1995-04-01), Blumenkopf
patent: 5543414 (1996-08-01), Nestor et al.
patent: 5559114 (1996-09-01), Exley
patent: 5580571 (1996-12-01), Hostetler
patent: 5585379 (1996-12-01), Sintov et al.
patent: 5627185 (1997-05-01), Gosselin et al.
patent: 5643891 (1997-07-01), Rideout et al.
patent: 5674849 (1997-10-01), Twist et al.
patent: 5677308 (1997-10-01), Lerner
patent: 5872123 (1999-02-01), Lerner
Harnden et al M.R., Prodrugs of the Selective Antiherpes Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl] guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties, J. Med. Chem., vol. 32, 1738 (1989).
Abstract No. 106:113183n, Van der Horst, C., et al., Differential effect on acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl) guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line, Chemical Abstracts--Pharmacology, vol. 106, p. 21 (1987).
Abstract No. 106:168524e, Faerber, I., et al., Effect of (E)-5-(2-bromovinyl) and 5-vinyl-B-(D)-arabinofuranosyluracil on Epstein-Barr virus antigen expression in P3HR-1 cells: comparison with acyclovir, Chemical Abstracts, vol. 106, p. 22 (1987).
Abstract No. 125:157838b, Tynell, E., et al., Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo controlled study, Chemical Abstracts--Pharmacology, vol. 125, p. 43 (1996).
Abstract No. 122:204641g, Ertl, P., et al., A comparative study of the in vitro and in vivo antiviral of acyclovir and penciclovir, Chemical Abstracts--Pharmacology, vol. 122, p. 36 (1995).
Abstract No. 120:260453t, Hughes, P., et al., Effect of acylation on the ocular disposition of acyclovir.I: Synthesis, physiochemical properties, and antiviral activity of 2'-esters, Chemical Abstracts--Pharmacology, vol. 120, p. 15 (1994).
Abstract No. 109:121992c, Lin, J.C., et al., Comparison of two bromovinyl nucloeside analogs, 1-B-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication, Chemical Abstracts, vol. 109, p. 14 (1988).
Abstract No. 123:47449b, Bacon, T., et al., Activity of peniclovir against Epstein-Barr virus, Chemical Abstracts, vol. 123, p. 30 (1995).
Abstract No. 126:165990f, Webster, A., et al., Developments in anti-herpes virus therapy, Chemical Abstracts--Pharmacology, vol. 126, p. 4 (1997).
Abstract No. 126:194733e, Acosta, E., et al., Valacyclovir, Chemical Abstracts--Pharmacology, vol. 126, p. 6 (1997).
Abstract No. 126:210p, Perry, C., et al., Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesivirus infections, Chemical Abstracts--Pharmacology, vol. 126, p. 16 (1997).
Perry et al, 126CA:210, 1996.
Crooks et al, 121CA:194728, 1994.
Ertl et al, 122CA:204641, 1995.
Datta et al, 94CA:10887, 1980.
LandOfFree
Treatment of Epstein Barr infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of Epstein Barr infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Epstein Barr infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-581397